Abstract
Although chemotherapy is indispensable for the treatment of ovarian cancer, secondary acute leukemia has become increasingly important as one of the most unfavorable late effects according to widespread long-term chemotherapy. We report a patient suffering from acute nonlymphocytic leukemia (ANLL) 3 years after treatment for stage IV ovarian cancer began.
MeSH terms
-
Antibiotics, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biopsy
-
Bone Marrow / pathology
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cystadenocarcinoma, Mucinous / drug therapy*
-
Cystadenocarcinoma, Mucinous / secondary
-
Cystadenocarcinoma, Mucinous / surgery
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Humans
-
Idarubicin / therapeutic use
-
Leukemia, Myeloid, Acute / chemically induced*
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / pathology
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Middle Aged
-
Mitoxantrone / therapeutic use
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology
-
Ovarian Neoplasms / surgery
-
Prednisolone / therapeutic use
-
Remission Induction / methods
-
Reoperation
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents, Alkylating
-
Cytarabine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone
-
Mitoxantrone
-
Cisplatin
-
Idarubicin
-
Daunorubicin